Nov 19, 2010 · The Thalidomide-Dexamethasone (TD) regimen has provided encouraging results in relapsed MM. To improve results, bortezomib (Velcade) has ...
People also ask
What is the difference between Velcade and bortezomib?
Why is dexamethasone given with bortezomib?
How effective is bortezomib for multiple myeloma?
What does Velcade do for multiple myeloma?
Apr 12, 2012 · The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation.
Missing: relapsing | Show results with:relapsing
The Thalidomide-Dexamethasone (TD) regimen has provided encouraging results in relapsed MM. To improve results, bortezomib (Velcade) has been added to the ...
Conclusion: VTD was more effective than TD in the treatment of patients with MM with progressive or relapsing disease post-ASCT but was associated with a higher ...
Missing: (Velcade superior
The delay in disease progression observed with CRd was clinically relevant and appeared superior (albeit based on indirect comparisons) to available triple- ...
Dec 10, 2010 · VTD induction therapy before double autologous stem-cell transplantation significantly improves rate of complete or near complete response.
Lenalidomide-bortezomib-dexamethasone resulted in partial response or better in nearly two-thirds of relapsed/refractory myeloma patients.
Aug 21, 2024 · The other active regimens for this patient population include continuous lenalidomide and dexamethasone or bortezomib (Velcade), melphalan, and ...
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation ...
VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimyeloma therapy.
